Aberdeen Wealth Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Aberdeen Wealth Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-500	Closed	–	–	163
2020 Q4	$0	Sell	500 -250	-33%	-$533	﹤0.01%	160
2020 Q3	$2K	Hold	750	–	–	﹤0.01%	132
2020 Q2	$3K	Hold	750	–	–	﹤0.01%	126
2020 Q1	$3K	Hold	750	–	–	﹤0.01%	118
2019 Q4	$2K	Buy	+750	New	+$1.95K	﹤0.01%	153

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Aberdeen Wealth Management's BMY.RT Position: Q1 2021 in Review

Aberdeen Wealth Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 500 shares.

Aberdeen Wealth Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Aberdeen Wealth Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Aberdeen Wealth Management sold 500 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
Aberdeen Wealth Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Aberdeen Wealth Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3K in Q2 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Aberdeen Wealth Management's 13F filing for Q1 2021, filed 13 May 2021.